Organon & Co. cash flow to debt ratio of 7.95% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Organon & Co.'s free cash flow has decreased 8.50% from $588.00M last year to $538.00M, signaling decreasing performance

Organon & Co.'s debt to equity ratio is 8.50, which means that the company's assets are unhealthy financed, signaling financial risk.

Organon & Co.'s debt has decreased relative to shareholder equity from 19.14 last year to 8.50 today, signaling strengthened financials

Organon & Co. has a net debt to EBITDA ratio of 6.41x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Organon & Co.'s interest coverage ratio of 2.53 indicates that earnings with margin can cover interest payments on company debt

Organon & Co.'s profit margin has decreased (74.72%) in the last year from 13.49% to 3.41%, signaling decreasing performance

Organon & Co.'s short-term assets of $4.35B exceed its short-term liabilities of $2.39B

Organon & Co.'s return on assets of 1.59% is lower than the 5.00% threshold, indicating inefficient asset utilization

Organon & Co.'s return on equity of 23.44%, is higher than 15.00%, indicating good performance

Organon & Co.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Organon & Co. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Organon & Co. has positive free cash flow, indicating the company generates cash after capital expenditures

Organon & Co. has a free cash flow yield of 15.04%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Organon & Co.'s yearly earnings has decreased 78.36% since last year from $864.00M to $187.00M, signaling decreasing performance

Organon & Co.'s yearly revenue has decreased 2.92% since last year from $6.40B to $6.22B, signaling decreasing performance

ROIC 4.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Organon & Co.'s 3-year revenue CAGR of 0.23% is positive, indicating growing revenue over the past 3 years

Organon & Co. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Organon & Co. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Organon & Co. has insufficient data to evaluate this check.

Organon & Co. has an earnings yield of 5.84%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Organon & Co. is overvalued relative to its fair value price of 2.89 based on EBITDA multiple model

Organon & Co. has an EV/EBITDA ratio of 9.20x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Organon & Co. has insufficient data to evaluate this check.

Organon & Co.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Organon & Co. has a price-to-book ratio of 3.56x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Organon & Co. has a price-to-sales ratio of 0.58x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue